Enlivex Therapeutics Stock Jumps On Initiation Of Another Mid-Stage COVID-19 Trial

The Israeli Ministry of Health has signed off Enlivex Therapeutics Ltd's ENLV Phase 2b trial evaluating Allocetra in severe and critical COVID-19 patients with the acute respiratory distressed syndrome (ARDS).
The Phase 2b trial will recruit up to 152 severe or critical COVID-19 patients in clinical centers in Israel and certain European countries.
The trial is designed to assess the safety and efficacy of Allocetra when administered in addition to standard of care treatment.
The planned Phase 2b trial will have two primary endpoints: ventilation-free survival and recovery.
In addition, the trial will assess several secondary endpoints, including evaluation of long-COVID-19 symptoms.
Enlivex previously reported positive top-line results from Phase 1b and Phase 2 investigator-initiated trials.
Aggregate data from the two trials demonstrated that Allocetra was safe and well-tolerated.
At the end of the 28-day follow-up period, a 0% (0/21) mortality rate was observed.
90.5% (19/21) of patients recovered from their respective severe/critical condition and were discharged from the hospital after an average of 5.6 days following Allocetra administration.
Price Action: ENLV shares are up 21.80% at $12.39 during the premarket session on the last check Monday.